Skip to main content

Oxford GlycoSciences, Novartis to Work with Incyte on Databases


PALO ALTO, Calif.--Earlier this month, Incyte Pharmaceuticals here announced a joint venture with Oxford GlycoSciences in which the two companies will develop proteomics databases for humans, animals, plants, and microbes. In another deal, the company also said it has entered a multiyear collaboration that gives Novartis access to Incyte's LifeSeq database.

In the proteomics venture, Incyte will contribute its genomics and bioinformatics capabilities--including database architecture and software and data analysis--and also make a $5 million investment in Oxford, which will provide proteomics technologies. The partners will share profit and intellectual property rights. The arrangement also gives Oxford access to certain Incyte databases for use in its glycobiology-based drug discovery programs, while Incyte gains access to Oxford's high-throughput protein expression analysis technology.

Meanwhile, in the deal with Novartis, Incyte will receive annual access fees for use of the database and could earn royalties on sales of products developed with LifeSeq.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.